Leveraging Tumour Resistance Models to Empower ADC Development & Overcome Resistance Mechanisms
- Spotlighting the development of predictive preclinical resistance models
- Uncovering mechanistic insights into intrinsic and acquired resistance pathways
- Dissecting efficacy and linker properties using these models to improve the clinical translatability of ADC therapies